Asia Economist and CEO, Centennial Asia Advisors

Manu Bhaskaran

Asia Economist and CEO

Centennial Asia Advisors

At Centennial Asia Advisors, we tell it like it is. We have no vested interests, no need for a China wall, and no reason to skew our outlook any other way. With over 30 years experience covering Asia’s political economy, you can be sure our conclusions and analyses are based on the unadulterated facts. Through years of fine-tuning our research methodologies, we deliver a quality of macroeconomic analysis few other houses can match.

Centennial Asia Advisors is an independent research and advisory firm that works with governments, multilateral institutions, financial firms and leading MNCs.

Economic Policy and Strategic Advisors

Macroeconomics

<p>The death of <a href="http://www.rememberingleekuanyew.sg/" target="_blank">Lee Kuan Yew</a>&nbsp;takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep sadness for all Singaporeans including those of us at <a href="http://www.centennialasia.com/" target="_blank">Centennial Asia</a>.</p><p>His extraordinary leadership at crucial moments in Singapore&rsquo;s history - the traumatic merger and then separation with Malaysia, the confrontation with Indonesia, ethnic tensions, and countless economic challenges and crises - made what is Singapore today. His record of decisiveness and pragmatism and his success in creating strong institutions and a durable national consensus that unites the country mark him out from other leaders of developing nations.</p><blockquote><p>Some analysts have suggested that his passing could weaken Singapore, perhaps even create some political instability. The evidence suggests otherwise.</p></blockquote>

The death of Lee Kuan Yew&nbsp;takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep sadness for all Singaporeans including those of us at Centennial Asia.His extraordinary leadership at crucial moments in Singapore&rsquo;s history - the traumatic merger and then separation with Malaysia, the confrontation with Indonesia, ethnic tensions, and countless economic challenges and crises - made what is Singapore today. His record of decisiveness and pragmatism and his success in creating strong institutions and a durable national consensus that unites the country mark him out from other leaders of developing nations.Some analysts have suggested that his passing could weaken Singapore, perhaps even create some political instability. The evidence suggests otherwise.

Singapore: Lee Kuan Yew's enduring legacy of strong institutions will see Singapore through

Founder of Innovation Research & Advisory firm, Lightbulb Capital

Daniel Liebau

Founder of Innovation Research & Advisory firm

Lightbulb Capital

Thematic (Sector/Industry)

<p>Companies across different industries are building Innovation centers&nbsp; in Singapore, Hong Kong and other cities across Asia and the rest of the world.&nbsp; <br></p><p>Some examples include <a target="_blank" href="http://aia-accelerator.com/">AIA</a>, <a target="_blank" href="http://www.3m.com.hk/intl/hk/english/in_hongkong/innovation_center.html">3M</a>, <a target="_blank" href="http://www.mis-asia.com/tech/industries/metlife-announces-futurelab-in-singapore/">MetLife</a> and <a target="_blank" href="https://www.edb.gov.sg/content/edb/en/news-and-events/news/2014-news/p-and-g-opens-250-million-innovation-centre.html">P&amp;G</a> amongst others.&nbsp;</p><p>While this is a good step in the right direction there are 4 specific points that are worth considering to gauge if the initiative has a chance to create some optionality for future long term growth. Therefore, from an investment perspective it makes sense to evaluate Innovation initiatives in target companies with those points in mind.<br></p>

Companies across different industries are building Innovation centers&nbsp; in Singapore, Hong Kong and other cities across Asia and the rest of the world.&nbsp;  Some examples include AIA, 3M, MetLife and P&amp;G amongst others.&nbsp;While this is a good step in the right direction there are 4 specific points that are worth considering to gauge if the initiative has a chance to create some optionality for future long term growth. Therefore, from an investment perspective it makes sense to evaluate Innovation initiatives in target companies with those points in mind. 

Can Innovation labs be assessed to pick stocks for your portfolio?

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/global-cord-blood-corp" target="_blank" data-smartkarma-citation="entities:689:1" rel="noopener">Global Cord Blood (CO US)</a> is facing regulatory and business environment uncertainty. China has not released any update on the new licenses of the country’s new cord blood bank.</li>
<li>The company is seeing slower than expected business recovery and new subscriber addition is decelerating since Q1 FY22, mainly due to COVID-related restrictions.  </li>
<li>China’s birth rate dropped to a record low in 2021, thereby indicating sluggishness in the total addressable market of Global Cord.</li>
</ul>



Global Cord Blood (CO US) is facing regulatory and business environment uncertainty. China has not released any update on the new licenses of the country’s new cord blood bank.
The company is seeing slower than expected business recovery and new subscriber addition is decelerating since Q1 FY22, mainly due to COVID-related restrictions.  
China’s birth rate dropped to a record low in 2021, thereby indicating sluggishness in the total addressable market of Global Cord.


Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation

<ul>
<li>
<a href="https://www.smartkarma.com/entities/global-cord-blood-corp" target="_blank" data-smartkarma-citation="entities:689:1" rel="noopener">Global Cord Blood (CO US)</a> shares are trading within a range and are expected to have limited upsides due to ongoing merger and policy overhangs.</li>
<li>The ongoing acquisition proposal from Haitong values the company at a steep discount to the peers and one recently concluded deal in the similar space.</li>
<li>The company reported muted Q2 results with flat q/q revenue growth and new subscriber adds. Surge in new Covid cases in China may prolong the business recovery.   </li>
</ul>



Global Cord Blood (CO US) shares are trading within a range and are expected to have limited upsides due to ongoing merger and policy overhangs.
The ongoing acquisition proposal from Haitong values the company at a steep discount to the peers and one recently concluded deal in the similar space.
The company reported muted Q2 results with flat q/q revenue growth and new subscriber adds. Surge in new Covid cases in China may prolong the business recovery.   


Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe

Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<p>For our upcoming Corporate Webinar we are glad to welcome <a href="https://www.smartkarma.com/entities/cordlife-group-ltd" target="_blank" data-smartkarma-citation="entities:568" rel="noopener">Cordlife (CLGL SP)</a>'s group CEO, Tan Poh Lan, and the group CFO, <a href="https://www.smartkarma.com/profiles/boon-yong-choo-725534f2-040a-4254-afe7-8305a6c68e14" target="_blank" rel="noopener">Choo Boon Yong</a>.</p><h3>The Corporate Webinar will be hosted on Tuesday, 23 November 2021, 17:00 SGT.</h3><div class="content-highlight"><h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=84842690230" target="_blank" rel="noopener">Register for the Webinar here</a></h2></div><p>Established in May 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a leading company dedicated to safeguarding the well-being of mother and child. The Group was listed on the Mainboard of the Singapore Exchange in 2012 and is a pioneer in private cord blood banking in Asia.</p><p>Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets - namely Singapore, Hong Kong, Indonesia, India, Malaysia, and the Philippines. Beyond cord blood, cord lining, and cord tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening, and family genetic screening services. Quality and customer focus are amongst some of the cornerstones of Cordlife. </p><p>In their upcoming webinar, Boon Yong will share a short company presentation after which, Poh Lan and Boon Yong will engage in a fireside chat with Smartkarma Insight Provider, <a href="https://www.smartkarma.com/profiles/xinyao-criss-wang" target="_blank" rel="noopener">Xinyao (Criss) Wang</a>. The Corporate Webinar will include a live Q&amp;A session.</p>

For our upcoming Corporate Webinar we are glad to welcome Cordlife (CLGL SP)'s group CEO, Tan Poh Lan, and the group CFO, Choo Boon Yong.The Corporate Webinar will be hosted on Tuesday, 23 November 2021, 17:00 SGT.Register for the Webinar hereEstablished in May 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a leading company dedicated to safeguarding the well-being of mother and child. The Group was listed on the Mainboard of the Singapore Exchange in 2012 and is a pioneer in private cord blood banking in Asia.Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets - namely Singapore, Hong Kong, Indonesia, India, Malaysia, and the Philippines. Beyond cord blood, cord lining, and cord tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening, and family genetic screening services. Quality and customer focus are amongst some of the cornerstones of Cordlife. In their upcoming webinar, Boon Yong will share a short company presentation after which, Poh Lan and Boon Yong will engage in a fireside chat with Smartkarma Insight Provider, Xinyao (Criss) Wang. The Corporate Webinar will include a live Q&amp;A session.

Smartkarma Corporate Webinar | Cordlife: Stem Cell Banking in Asia

Singapore

Cordlife Group Limited is a consumer health company specializing in cord blood and cord lining banking services, as well as a comprehensive suite of diagnostic services for mother and child. Key offerings include cord blood, cord lining, and cord tissue banking, alongside newborn metabolic screening and non-invasive prenatal testing. The company was founded in May 2001 and is headquartered in Singapore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cordlife (CLGL SP)

Singapore: Lee Kuan Yew's enduring legacy of strong institutions will see Singapore through

The death of Lee Kuan Yew takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep...

Manu Bhaskaran

Can Innovation labs be assessed to pick stocks for your portfolio?

Companies across different industries are building Innovation centers in Singapore, Hong Kong and other cities across Asia and the rest of the...

Daniel Liebau

Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation

Global Cord seems to be an undervalued business, however, regulatory uncertainty, decelerating subscribers addition, and declining birth rate in...

Tina Banerjee

Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe

Global Cord reported muted Q2 results with revenue and new subscribers sign-ups remaining flat sequentially, representing slower recovery. Shares...

Tina Banerjee

Smartkarma Corporate Webinar | Cordlife: Stem Cell Banking in Asia

On 23 November, 5pm SGT, join our Corporate webinar with Cordlife group CEO Tan Poh Lan and group CFO Choo Boon Yong, speaking to Insight Provider...

Smartkarma Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)